Search

everythinglearnresearchcommunity

for

Search:↓

Baricitinib is effective and safe for long-term use in severe alopecia areata, improving hair regrowth and quality of life with few side effects.

JAK inhibitors are safe and effective for treating moderate-to-severe alopecia areata.

Blocking the enzyme that turns testosterone into DHT can safely and effectively treat enlarged prostate.

Scalp cooling can prevent chemotherapy-induced hair loss, and certain treatments can speed up hair regrowth, but more research is needed for better treatments.

Timosaponin BII, a plant extract, was found to promote hair growth in mice, similarly to minoxidil.

Baricitinib helps improve hair growth in severe alopecia, with better results in less severe cases and higher doses working faster.

Baricitinib was effective in regrowing hair in patients with different levels of alopecia areata severity.

Self-monitoring blood pressure in pregnant women didn't improve outcomes, diabetes drugs may increase gallbladder disease risk, a new drug helps severe hair loss, a plant-based COVID-19 vaccine is 69.5% effective, and new anticoagulants are safer for diabetics with heart rhythm issues than warfarin.

The current system can't fully test all combination treatments, so alternative methods and regulatory flexibility are needed.

A new protein linked to Alzheimer's was discovered, and a hair loss treatment showed effectiveness but had some sexual side effects.

Baricitinib effectively treats severe alopecia for up to 104 weeks.

Baricitinib is a relatively safe and effective treatment for severe alopecia areata.

The botanical treatment for hair loss shows promise, especially for children.

Giving docetaxel weekly at 40 mg/m² is manageable and has low toxicity for cancer patients.

Rivaroxaban can cause liver injury, allergic reactions, blood vessel inflammation, and hair loss, but these side effects are rare.

Many potential alopecia treatments need more testing to confirm they promote acceptable hair growth with minimal side effects.

There are several promising treatments for hair loss, including dutasteride, latanoprost, ketoconazole shampoo, anti-androgens, laser/light treatment, and platelet-rich plasma, but more research is needed.

Niosomes are a promising, stable, and cost-effective drug delivery system with potential for improved targeting and safety.

The enzyme steroid sulfatase is linked to breast cancer and other conditions, and inhibitors are being developed for treatment.

Patients and doctors often agree on the severity of eyebrow and eyelash hair loss in severe alopecia areata.

The new clinical trial design is promising but needs real-world trials to test its effectiveness and possible enhancements.

Baricitinib improved severe hair loss in adults over 52 weeks and was safe to use.

Targeting glucocorticoid action might help treat type-2 diabetes, but human trials are needed.

The oral contraceptive with ethinyl estradiol and chlormadinone acetate is effective in treating moderate acne.

Once-daily 5% minoxidil foam increases hair regrowth and density in women with hair loss, but not as effectively as twice-daily 2% minoxidil solution, though it's safer and more convenient.

The drug IPI-926 is safe at 160 mg daily and may help treat certain tumors, especially basal cell carcinoma.

A patient with Alopecia Areata had complete hair regrowth after using the drug baricitinib.

New compounds were found to help increase hair growth and decrease hair loss.

Docetaxel and oxaliplatin are effective and have manageable side effects for recurrent platinum-sensitive ovarian cancer.

The BJUI supports clinical trials as key for unbiased medical evidence and works to enhance their design, reporting, and discussion.